Ken Griffin Marker Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.26 - $0.46 $33,231 - $58,793	127,813 Added 774.39%	144,318 $48,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $5,860 - $10,610	-6,169 Reduced 27.21%	16,505 $15,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $454,204 - $778,636	-270,360 Reduced 92.26%	22,674 $38,000
Q2 2021 Aug 16, 2021	BUY	$1.88 - $3.56 $209,294 - $396,324	111,327 Added 61.27%	293,034 $817,000
Q1 2021 May 17, 2021	BUY	$1.47 - $3.29 $198,692 - $444,692	135,165 Added 290.42%	181,707 $407,000
Q4 2020 Feb 16, 2021	SELL	$1.36 - $1.75 $2,992 - $3,850	-2,200 Reduced 4.51%	46,542 $67,000
Q3 2020 Nov 16, 2020	BUY	$1.5 - $2.2 $1,591 - $2,334	1,061 Added 2.23%	48,742 $73,000
Q2 2020 Aug 14, 2020	SELL	$1.69 - $2.79 $27,241 - $44,972	-16,119 Reduced 25.26%	47,681 $99,000
Q1 2020 May 15, 2020	BUY	$1.59 - $3.35 $101,442 - $213,730	63,800 New	63,800 $121,000
Q4 2019 Feb 14, 2020	SELL	$2.68 - $4.85 $234,797 - $424,913	-87,611 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.1 - $9.0 $359,205 - $788,499	87,611 New	87,611 $447,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $164M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.